Review of cancer treatment with immune checkpoint inhibitors

被引：98

作者：

Thallinger, Christiane ^{[1
,2
,3
]}

Fuereder, Thorsten ^{[1
,3
]}

Preusser, Matthias ^{[1
,3
]}

Heller, Gerwin ^{[1
,3
]}

Muellauer, Leonhard ^{[4
]}

Hoeller, Christoph ^{[5
]}

Prosch, Helmut ^{[6
]}

Frank, Natalija ^{[3
]}

Swierzewski, Rafal ^{[7
]}

Berger, Walter ^{[8
]}

Jaeger, Ulrich ^{[9
]}

Zielinski, Christoph ^{[1
,2
,3
]}

机构：

[1] Gen Hosp, Dept Med 1, Div Clin Oncol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria

[2] Cent European Cooperat Oncol Grp, Vienna, Austria

[3] Med Univ Vienna, Gen Hosp, Ctr Comprehens Canc, Vienna, Austria

[4] Med Univ Vienna, Gen Hosp, Dept Pathol, Vienna, Austria

[5] Med Univ Vienna, Gen Hosp, Dept Dermatol, Vienna, Austria

[6] Med Univ Vienna, Gen Hosp, Dept Radiol, Vienna, Austria

[7] ECPC, Brussels, Belgium

[8] Med Univ Vienna, Inst Canc Res, Dept Med 1, Vienna, Austria

[9] Med Univ Vienna, Dept Med 1, Clin Div Hematol, Vienna, Austria

来源：

WIENER KLINISCHE WOCHENSCHRIFT | 2018年 / 130卷 / 3-4期

关键词：

Cancer; Immunotherapy; PD-1; Experts; Review; CELL LUNG-CANCER; REGULATORY T-CELLS; ADVERSE EVENTS; PD-1; BLOCKADE; UROTHELIAL CARCINOMA; METASTATIC MELANOMA; 1ST-LINE TREATMENT; RESPONSE CRITERIA; IMMUNOTHERAPY; THERAPY;

D O I：

10.1007/s00508-017-1285-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immunotherapy by checkpoint inhibition is about to profoundly change cancer therapy. The number of indications are growing at an unprecedented speed. Clinical studies have demonstrated efficacy in a variety of solid tumors and in hematologic malignancies, although some clinical trials have produced negative results. Thus, it is fair to assume that there are obvious limitations and pitfalls in immunotherapy. Future concepts for combination treatment of immune checkpoint inhibitors have to be developed, but there is also urgent need for better and standardized biomarkers to identify those cancer patients who will benefit from treatment by checkpoint inhibition. The current overview summarizes current knowledge on immune checkpoint inhibitor treatment in malignancies, its outlook and limitations, diagnostic means and, finally, side effect management.

引用

页码：85 / 91

页数：7

共 62 条

[1] The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy [J].

Ahn, Sung-Min ;

Ansari, Adnan Ahmad ;

Kim, Jihun ;

Kim, Deokhoon ;

Chun, Sung-Min ;

Kim, Jiyun ;

Kim, Tae Won ;

Park, Inja ;

Yu, Chang-Sik ;

Jang, Se Jin .

ONCOTARGET, 2016, 7 (42) :68638-68649

[2] PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher [J].

Allen, Pamela Blair ;

Gordon, Leo I. .

EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (10) :939-949

[3] Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer [J].

Anagnostou, Valsamo ;

Smith, Kellie N. ;

Forde, Patrick M. ;

Niknafs, Noushin ;

Bhattacharya, Rohit ;

White, James ;

Zhang, Theresa ;

Adleff, Vilmos ;

Phallen, Jillian ;

Wali, Neha ;

Hruban, Carolyn ;

Guthrie, Violeta B. ;

Rodgers, Kristen ;

Naidoo, Jarushka ;

Kang, Hyunseok ;

Sharfman, William ;

Georgiades, Christos ;

Verde, Franco ;

Illei, Peter ;

Li, Qing Kay ;

Gabrielson, Edward ;

Brock, Malcolm V. ;

Zahnow, Cynthia A. ;

Baylin, Stephen B. ;

Scharpf, Robert B. ;

Brahmer, Julie R. ;

Karchin, Rachel ;

Pardoll, Drew M. ;

Velculescu, Victor E. .

CANCER DISCOVERY, 2017, 7 (03) :264-276

[4] Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure [J].

Armand, Philippe ;

Shipp, Margaret A. ;

Ribrag, Vincent ;

Michot, Jean-Marie ;

Zinzani, Pier Luigi ;

Kuruvilla, John ;

Snyder, Ellen S. ;

Ricart, Alejandro D. ;

Balakumaran, Arun ;

Rose, Shelonitda ;

Moskowitz, Craig H. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) :3733-+

[5] Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer [J].

Aydin, Ahmet Murat ;

Woldu, Solomon L. ;

Hutchinson, Ryan C. ;

Boegemann, Martin ;

Bagrodia, Aditya ;

Lotan, Yair ;

Margulis, Vitaly ;

Krabbe, Laura-Maria .

ONCOTARGETS AND THERAPY, 2017, 10 :1487-1502

[6] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[7] Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma [J].

Beckermann, Kathryn E. ;

Jolly, Pradeep C. ;

Kim, Ju Y. ;

Bordeaux, Jennifer ;

Puzanov, Igor ;

Rathmell, W. Kimryn ;

Johnson, Douglas B. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5

[8] PD-1/PD-L1 blockade in renal cell cancer [J].

Beckermann, Kathryn E. ;

Johnson, Douglas B. ;

Sosman, Jeffrey A. .

EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (01) :77-84

[9] Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis [J].

Bertrand, Anne ;

Kostine, Marie ;

Barnetche, Thomas ;

Truchetet, Marie-Elise ;

Schaeverbeke, Thierry .

BMC MEDICINE, 2015, 13

[10] Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy [J].

Calvo, Emiliano ;

Schmidinger, Manuela ;

Heng, Daniel Y. C. ;

Gruenwald, Viktor ;

Escudier, Bernard .

CANCER TREATMENT REVIEWS, 2016, 50 :109-117

← 1 2 3 4 5 6 7 →